John Horton

Biography

John is a medical practitioner with 25 years experience in drug development in industry. For the last 17 years John has worked exclusively in Developing World Medicine – malaria, helminths, leishmaniasis, diarrhoea etc. and was the moving force and "father figure" of the tropical disease initiatives in GlaxoSmithKline (GSK). John was closely involved in establishing the Medicines for Malaria Venture and the Global Alliance for TB Drug Development, and was a member of GATB scientific advisory committee. At GSK, John ensured involvement in 3 Public Private Partnerships with the WHO (Lapdap, Lapdap + artesunate and an early stage antimalarial) and in developing concepts for access in public health to these products. John was intimately involved in establishing the Global Programme to Eliminate Lymphatic Filariasis (GPELF), having initiated both the original studies that formed the basis of the programme, and the concepts behind the global programme. Over the years John has acted as an advisor in a number of WHO programme initiatives (e.g. global helminth elimination). Although now retired from GSK, John continues to work part time for WHO in their drug development programmes, and holds academic appointments in Liverpool and in Perth, and is a founding trustee of the Malaria Consortium, a UK NGO.

Research Interest

John is a medical practitioner with 25 years experience in drug development in industry. For the last 17 years John has worked exclusively in Developing World Medicine – malaria, helminths, leishmaniasis, diarrhoea etc. and was the moving force and "father figure" of the tropical disease initiatives in GlaxoSmithKline (GSK). John was closely involved in establishing the Medicines for Malaria Venture and the Global Alliance for TB Drug Development, and was a member of GATB scientific advisory committee. At GSK, John ensured involvement in 3 Public Private Partnerships with the WHO (Lapdap, Lapdap + artesunate and an early stage antimalarial) and in developing concepts for access in public health to these products. John was intimately involved in establishing the Global Programme to Eliminate Lymphatic Filariasis (GPELF), having initiated both the original studies that formed the basis of the programme, and the concepts behind the global programme. Over the years John has acted as an advisor in a number of WHO programme initiatives (e.g. global helminth elimination). Although now retired from GSK, John continues to work part time for WHO in their drug development programmes, and holds academic appointments in Liverpool and in Perth, and is a founding trustee of the Malaria Consortium, a UK NGO.